Skip to Late-Breaking Abstracts »
All accepted abstracts are available in the Journal for ImmunoTherapy of Cancer (JITC).
Abstract Titles
Poster Presentation Dates
All odd numbered posters will be presented on Wednesday, Nov. 11, from 5:15-5:45 p.m. EST and Friday, Nov. 13, from 4:40-5:10 p.m. EST. Even numbered posters will be presented on Thursday, Nov. 12, from 4:50-5:20 p.m. EST and Saturday, Nov. 14, from 1-1:30 p.m. EST.
Posters will be on display from 8 a.m. on Monday, Nov. 9, until the virtual poster hall closes on December 31, 2020.
| # | Type | Title | Authors | Category | Keywords |
|---|---|---|---|---|---|
| 257 | Poster Presentation | Development of a Diagnostic Platform Which Matches Therapies to the Tumor Microenvironment Dominant Biology | Kristen Strand-Tibbitts, PhD; | Completed Clinical Trials | Angiogenesis; Bioinformatics; Tumor microenvironment; Tumor stroma |
| 258 | Poster Presentation | Scientific correlatives from LCCC 1525: A Phase II Study of a Priming Dose of Cyclophosphamide Prior to Pembrolizumab to Treat Metastatic Triple Negative Breast Cancer | Mark G. Woodcock, MD; Carey K. Anders, MD; Amanda E. Van Swearingen; Dominic T. Moore; Maria J. Sambade; Luz A. Cuaboy; Amy L. Garrett; Karen McKinnon; Kristen Cowens; Dante S. Bortone; Benjamin C. Calhoun; Lisa Carey; Claire Dees; Trevor Jolly; Hyman Muss; Katherine Reeder-Hayes; Rebecca Kaltman; Rachel Jankowitz; Vinay Gudena; Oludamilola Olajide; Charles M. Perou; Benjamin G. Vincent, MD; Jonathan S. Serody, MD; | Completed Clinical Trials | B cell; Checkpoint blockade; Clinical trial; Gene expression; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor microenvironment |
| 259 | Poster Presentation | Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + selicrelumab (seli) + gemcitabine+nab-paclitaxel (gem+nabP) or bevacizumab (bev) vs control in MORPHEUS-PDAC, -TNBC and -CRC | Gulam A. Manji, MD PhD; Nathan Bahary, MD PhD; Vincent Chung, MD; Florence Dalenc; Michel Ducreux; Carlos A. Gomez-Roca, MD; Seock-Ah Im; Jeremy Kortmansky; Jill Lacy, MD; Neil H. Segal, MD; Olivier Tredan; Olivera Cirovic, MD, PhD; Kelly DuPree; Christelle Lenain; Danny Lu; Lidia Robert; Jeffrey Xu; Xiaosong Zhang, MD PhD; Sung-Bae Kim; | Completed Clinical Trials | Checkpoint blockade; Chemotherapy; Clinical trial |
| 260 | Poster Presentation | T Cell Infiltrating Repertoire Diversity is Associated with Enhanced Survival Following Neoadjuvant Therapy in Patients with Resectable Pancreatic Cancer | Pranav Murthy, BS; Pragosh Saini; Kira L. Russell, BS; Wenjing Pan, PhD; Daniel Weber, BS; Miranda L. Byrne-Steele, PhD; Jian Han, MD PhD; Viginia Espina, PhD; Lance Liotta, MD, PhD; Herbert J. Zeh III, MD; Nathan Bahary, MD PhD; Aatur D. Singhi, MD PhD; Tullia C. Bruno, PhD; Amer H. Zureikat, MD; Michael T. Lotze, MD; | Completed Clinical Trials | B cell; Bioinformatics; Biomarkers; Chemotherapy; Immune contexture; Inflammation; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 261 | Poster Presentation | Association of T-cell–inflamed gene expression profile and PD-L1 status with efficacy of pembrolizumab in patients with esophageal cancer from KEYNOTE-180 | Manish A. Shah, MD; Takashi Kojima; Daniel Hochhauser; Peter M. Enzinger, MD; Judith Raimbourg; Antoine Hollebecque, MD; Florian Lordick; Sung-Bae Kim; Masahiro Tajika; Heung Tae Kim; A. Craig Lockhart; Hendrick-Tobias Arkenau; Farid El-Hajbi; Per Pfeiffer; Pooja Bhagia, MBBS, MD; Z. Alexander Cao; Jared Lunceford; Shailaja Suryawanshi; Mark Ayers, PhD; Matt Marton; Ken Kato, MD, PhD; | Completed Clinical Trials | Antibody; Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Gene expression; Solid tumors; Tumor microenvironment |
| 262 | Poster Presentation | Tumoral DKK1 expression correlates with better clinical outcomes in patients with advanced esophagogastric cancer (EGC) treated with DKN-01 | Samuel J. Klempner, MD; Michael Kagey, PhD; Cynthia Sirard, MD; Cynthia Sirard, MD; | Completed Clinical Trials | Antibody; Biomarkers; Clinical trial; RNA; Targeted therapy |
| 263 | Poster Presentation | Pleiotropic effects of IL-7 in prostate cancer patients receiving Sipuleucel-T vaccination | Caroline Duault, PharmD, PhD; Nirasha Ramchurren, PhD; Russell Pachynski, MD; Lawrence Fong, MD; Sean C. Bendall, PhD; Mina Pichavant; Bita Sahaf, PhD; Chihiro Morishima, MD; Leonard D'Amico, PhD; Martin A. Cheever, MD; Steven P. Fling, PhD; Holden T. Maecker, PhD; | Completed Clinical Trials | Antigen presenting cells; Clinical trial; Costimulation; Cytokine; Immune adjuvant; Immune monitoring; Solid tumors; Vaccine |
| 264 | Poster Presentation | Correlation of virus-specific CD8+ T cells to clinical response following treatment with Pexa-Vec and Cemiplimab in patients with advanced renal cell carcinoma | Myles Dillon, PhD; Lianjie Li, MD PhD; Jeongsook Bang, MS; Nicholas Gaspar, PhD; Jessica Kuhnert, BS; Nathalie M. Fiaschi, PhD; Vladimir Jankovic, MD; Israel Lowy, MD, PhD; Gavin Thurston, PhD; Glenn Kroog, MD; Kyoung Soo Ha, MD; Raquel Deering, PhD; Raquel Deering, PhD; | Completed Clinical Trials | Biomarkers; Checkpoint blockade; Clinical trial; Cytokine; T cell; Tumor microenvironment; Vaccine |
| 265 | Poster Presentation | Phase 1b study of avelumab + M9241 (NHS-IL12) in patients with advanced solid tumors: interim analysis results from a urothelial carcinoma (UC) dose-expansion cohort | Jean-Laurent Deville; Alain Ravaud; Marco Maruzzo; Theodore S. Gourdin, MD; Michele Maio, MD; Luc Dirix, MD; XiaoZhe Wang; Yulia Vugmeyster; Frank Beier; Jeorg Seebeck; Sarah Chennoufi, MD, PhD; James L. Gulley, MD, PhD; James L. Gulley, MD, PhD; | Completed Clinical Trials | Antibody; Checkpoint blockade; Clinical trial; Cytokine; Solid tumors |
| 266 | Poster Presentation | Tumour mutation burden (TMB) and efficacy outcomes in the phase III DANUBE study of advanced urothelial carcinoma (UC) | Sophie Wildsmith; Jill Walker, PhD; Anne L’Hernault; Weimin Li; Hannah Bye; Philip He; Feng Xiao; Qu Zhang; Ross Stewart; Melissa de los Reyes, MS; Rajiv G. Raja, PhD; Wendy Levin; Ashok K. Gupta, MD, PhD; Thomas Powles, MBBS, MD, MRCP; Joaquim Bellmunt; Matthew D. Galsky, MD; Alexandra Drakaki, MD,PHD; Michiel van der Heijden, MD; | Completed Clinical Trials | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors |
| 267 | Poster Presentation | Pseudoprogression patterns: Analysis from 2 independent phase-2 studies with immunotherapy for recurrent cervical cancer | David M. O'Malley, MD; Waldo Ortuzar Feliu, MD; Isabelle Ray-Coquard, MDPhD; Michael O'Neal; Jerome Alexandre, MD; Julie Cole, MD; Robert Ludwig, MD; Madhavi Nallewar; Jennifer S. Buell, PhD; Remigiusz Kaleta, MD; Anna Wijatyk, MD; Victoria Borisovskaya; | Completed Clinical Trials | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Immune toxicity; Solid tumors |
| 268 | Poster Presentation | A phase 1 study of retifanlimab (INCMGA00012), a PD-1 inhibitor, in patients with advanced solid tumors: preliminary results in recurrent MSI-high or dMMR endometrial cancer (POD1UM-101) | Dominique Berton-Rigaud; Ignace Vergote; Patricia Pautier; Anna Kryzhanivska, MD; Antoine Angelergues; Deanna Kornacki, PhD; Monika Dudzisz-Sledz; Chuan Tian, PhD; Nawel Bourayou, MD; Frederic Selle; | Completed Clinical Trials | Antibody; Checkpoint blockade; Clinical trial; Solid tumors |
| 269 | Poster Presentation | Tumoral and peripheral landscape of Viral- versus Carcinogen-Driven Head and Neck Cancer | Tze Heng Tan; Sriram Sridhar; Helen K. Angell, PhD, BSc; Emma Jones; Amelia Raymond; Sophie Willis; Dimitris Polychronopoulos; Alejandro Yovine; Nassim Morsli; Patricia McCoon, PhD; Carl Barrett; Maria L. Ascierto, PhD; | Completed Clinical Trials | Biomarkers; Cytokine; Gene expression; Immune contexture; Immune monitoring; Tumor microenvironment |
| 270 | Poster Presentation | A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the thyroid tumor cohort | Young Kwang Chae, MD, MPH, MBA; Megan Othus; Sandip P. Patel, MD; Sarah E. Fenton, MD PhD; Ding Wang, MD; Cristina Rodriguez; Adedayo Onitilo; Ahmad H. Mattour, MD; Igor Rybkin, MD, PhD; Jourdain Hayward; Christine M. McLeod; Helen Chen, MD; Elad Sharon, MD, MPH; Edward Mayerson; Christopher W. Ryan; Melissa Plets, M.S.; Charles D. Blanke; Razelle Kurzrock, MD; Young Kwang Chae, MD, MPH, MBA; | Completed Clinical Trials | Checkpoint blockade; Clinical trial; Solid tumors |
| 271 | Poster Presentation | Consistent high-quality dendritic cell vaccines produced post-chemotherapy in patients with acute myeloid leukemia for use in a Phase I/II trial | Frauke Schnorfeil; Christiane Geiger, PhD; Iris Bigalke; Dag Josefsen; Yngvar Floisand; Gunnar Kvalheim, MD, PhD; Dolores J. Schendel, PhD; Anna Tafuri; Kai Pinkernell; | Completed Clinical Trials | Antigen presenting cells; Dendritic cell; Leukemia/Lymphoma; Targeted therapy; Tumor antigens; Vaccine |
| 272 | Poster Presentation | Use of LioCyx-M, Autologous Hepatitis B Virus (HBV)-Specific T cell receptor (TCR) T-cells, in Advanced HBV-related Hepatocellular Carcinoma (HCC) | Fu-Sheng Wang, MD, PhD; Fanping Meng, MD, PhD; Jiehua Jin, PhD; Yuanyuan Li, MD, PhD; Regina Wanju Wong, PhD; Anthony Tanoto Tan, PhD; Tingting Wang, MD, PhD; Antonio Bertoletti, MD; | Completed Clinical Trials | Adoptive immunotherapy; Clinical trial; T cell |
| 273 | Poster Presentation | Phase I Study of LioCyx-M, Autologous Hepatitis B Virus (HBV)-Specific T cell receptor (TCR) T-cells, in Recurrent HBV-Related Hepatocellular Carcinoma (HCC) Post-Liver Transplantation | Wenjie Chen, MD, PhD; Jintao Cheng, MD; Xiaofang Zheng, BSc; Fan Yang, MD, PhD; Royce Fam, BSc; Sarene Koh, PhD; Lu-En Wai, PhD; Tingting Wang, MD, PhD; Antonio Bertoletti, MD; Qi Zhang, MD, PhD; | Completed Clinical Trials | Adoptive immunotherapy; Clinical trial; T cell |
| 274 | Oral Presentation | Tumoral and peripheral immunophenotype of refractory vs relapse to PD-(L)1 blockade in patients with advanced Non-Small Cell Lung Cancer | Maria L. Ascierto, PhD; Matthew D. Hellmann, MD; Nathan Standifer; Song L. Wu; Han Si; Chris Morehouse; Marlon C. Rebelatto, DVM, PhD, DACVP; Shaad E. Abedin, MD, FACP; Rajiv G. Raja, PhD; Jean-Charles Soria, MD, PhD; Caroline Germa; Carl Barrett; | Completed Clinical Trials | B cell; Biomarkers; Checkpoint blockade; Tumor microenvironment |
| 275 | Poster Presentation | Translational endpoints associated with STK11 mutations in patients with non-squamous NSCLC | Song Wu; Nathan Standifer, PhD; Melissa de los Reyes, MS; Micheal Oberst; Rajv Raja; Carl Barrett; Maria L. Ascierto, PhD; Maria L. Ascierto, PhD; | Completed Clinical Trials | Biomarkers; Checkpoint blockade; Immune suppression; Tumor microenvironment |
| 276 | Poster Presentation | Prognostic value of tumor size varies by treatment in a meta-analysis of 15 randomized clinical trials in advanced non-small cell lung cancer across immunotherapy, TKI, and chemotherapy regimens | Jacqueline Buros, BA; Krzysztof Sakrejda, PhD; Daniel Lee, MS; Eric Novik, MS; Jacqueline Buros, BA; Philip Jewsbury, PhD; | Completed Clinical Trials | Biomarkers; Checkpoint blockade; Clinical trial |
| 277 | Oral Presentation | Combined neoadjuvant chemo-immunotherapy therapy achieves superior downstaging of resectable non-small cell lung cancer as compared to chemotherapy, mono or dual immunotherapy | Boris Sepesi, MD; Erin M. Corsini; Annikka Weissferdt; Apar Pataer; Mehmet Altan, MD; Mara B. Antonoff, MD; George R. Blumenschein, Jr., MD; Yasir Y. Elamin; Frank Fossella; Bonnie S. Glisson, MD; Wayne Hofstetter; Jonathan Kurie; Xiuning Le, MD, PhD; Cheuk Hong Leung, MS; Heather Lin, MS, PhD; Charles Lu; Reza Mehran; Frank Mott; David Rice; Jack Roth; Ferdinandos Skoulidis; Stephen G. Swisher, MD; Anne Tsao, MD; Ara A. Vaporciyan, MD; Garret Walsh; Jianjun Zhang, MD, PhD; Don L. Gibbons, MD, PhD; John V. Heymach, MD, PhD; Tina Cascone, MD, PhD; | Completed Clinical Trials | Checkpoint blockade; Chemotherapy; Clinical trial; Solid tumors; Surgery; Targeted therapy |
| 278 | Poster Presentation | Phase I clinical trial evaluating the safety of ADP-A2M10 SPEAR T-cells in patients with MAGE-A10+ advanced non-small cell lung cancer | George R. Blumenschein, Jr., MD; Siddhartha Devarakonda, MD; Melissa L. Johnson, MD; Victor Moreno, PhD, MD; Justin F. Gainor, MD; Martin Edelman, MD; John V. Heymach, MD, PhD; Ramaswamy Govindan, MD; Carlos Bachier, MD; Bernard Doger de Spéville; Matthew J. Frigault, MD, MSc; Anthony J. Olszanski, MD, RPh; Vincent K. Lam; Natalie Hyland; Jean-Marc Navenot, PhD; Svetlana Fayngerts, PhD; Jane Bai; Elliot Norry, MD; Paula M. Fracasso, MD, PhD | Completed Clinical Trials | Adoptive immunotherapy; Targeted therapy |
| 279 | Poster Presentation | Durvalumab after chemoradiotherapy for PD-L1 expressing inoperable stage III NSCLC impacts local-regional control and overall survival | MD; Lukas Kaesmann, MD; Julian Taugner; Chukwuka Eze; Claus Belka; Farkhad Manapov; | Completed Clinical Trials | Checkpoint blockade; Clinical trial; Radiotherapy; Solid tumors |
| 280 | Poster Presentation | Both tumor intrinsic and extrinsic factors contribute to TIL resistance in lung cancer patients | Chao Wang, PhD; Jamie Teer; Jiqiang Yao, PhD; Carmen Anadon; David Noyes; Ana Landin; Xiaoqing Yu; Dongliang Du; Zachary Thompson; Bin Fang, PhD; John M. Koomen, PhD; Sungjune Kim, MD PhD; Shari A. Pilon-Thomas, PhD; Dung-Tsa Chen; Jose R. Conejo-Garcia, MD, PhD; Scott J. Antonia, MD PhD; Eric Haura, MD; Ben C. Creelan, MD, MS; | Completed Clinical Trials | Adoptive immunotherapy; Neoantigens; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| 281 | Poster Presentation | JAVELIN Medley VEGF: phase 2 study of avelumab + axitinib in patients with previously treated non-small cell lung cancer (NSCLC) or treatment naive, cisplatin-ineligible urothelial cancer (UC) | Gabriella Galffy, MD; Iwona Lugowska; Elena Poddubskaya; Byoung Chul c. Cho, MD, PhD; Myung-Ju Ahn; Ji-Youn Han, MD, PhD; Wu-Chou Su; Ralph J. Hauke, MD; Stephen Dyar; Dae Ho Lee; Piotr Serwatowski; David Lorente Estelles; Viran Holden; Yu Jung Kim; Vladimir Vladimirov; Zsolt Horvath; Abhimanyu Ghose; Allison Goldman; Alessandra di Pietro; Jing Wang; Danielle Murphy; Mikhail Laskov | Completed Clinical Trials | Angiogenesis; Antibody; Checkpoint blockade; Clinical trial; Solid tumors; Targeted therapy |
| 282 | Poster Presentation | Pan-tumor analysis of the association between PD-L1 combined positive score and response to pembrolizumab monotherapy | Lingkang Huang; Jared Lunceford, PhD; Junshui Ma; Kenneth Emancipator, MD; | Completed Clinical Trials | Antibody; Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors |
| 283 | Poster Presentation | Safety and efficacy signals in the complete phase I study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (ICIs) | Shubham Pant, MD; Amishi Shah; Pavlos Msaouel, MD, PhD; Matthew T. Campbell, MD; Shi-Ming Tu; Jianjun Gao, MD PhD; George R. Blumenschein, Jr., MD; Frank Mott; Xiuning Le, MD, PhD; Mehmet Altan, MD; Funda Meric-Bernstam, MD; Timothy A. Yap, MD, PhD; Vivek Subbiah, MD; Jordi Rodon; Axel Glasmacher; Imke Mulder; Michael J. Chisamore, PhD; Alexander Stevenson, PhD; Nizar M. Tannir, MD, FACP; | Completed Clinical Trials | Checkpoint blockade; Clinical study; Clinical trial; Microbiome; Solid tumors; TLR |
| 284 | Poster Presentation | Real World Data of Sequencing Immune Checkpoint Inhibitors (ICI) after Initial ICI | Krishna S. Gunturu, MD; Muhammad A. Awidi, MD; Rojer Ranjit, NP; Brendan Connell, MD; Rachel Carrasquillo; Brigitte Gil; Natalie Dalbo, MD; Lewena Maher; Seanna Reilly; Stephanie McDonald, NP; Philip Tsoukas, MD; Linda Voner, RN; | Completed Clinical Trials | Checkpoint blockade; Clinical study; Clinical trial; Immune tolerance; Solid tumors |
| 285 | Poster Presentation | Phase I clinical trial evaluating the safety of ADP-A2M10 in patients with MAGE-A10+ head and neck, melanoma, or urothelial tumors | David S. Hong, MD; Marcus O. Butler, MD; Russell Pachynski, MD; Ryan J. Sullivan, MD; Partow Kebriaei; Sarah Boross-Harmer; Matthew J. Frigault, MD, MSc; Ecaterina I. Dumbrava, MD; Amy Sauer; Francine Brophy; Jean-Marc Navenot, PhD; Svetlana Fayngerts, PhD; Jane Bai; Elliot Norry, MD; Paula G. Fracasso | Completed Clinical Trials | Adoptive immunotherapy; Targeted therapy |
| 286 | Poster Presentation | Tumor targeting and tissue biodistribution of RO7122290, a novel FAP-targeted 4-1BB (CD137) agonist, in patients with advanced solid tumors, using [89Zr]-RO7122290 as a PET tracer | Maria Jose Garcia Velloso; Ivan Penuelas; Mariano Ponz-Sarvise; Miguel Sanmamed; Maria E. Rodriguez-Ruiz, MD, PhD; Ignacio J. Melero, Dr., MD, PhD; Danielle Vugts; Ronald Boellaard; Marc Huisman; Guus van Dongen; Ernesto Guarin; Florian Heil; Maurizio Ceppi, PhD; Marta Canamero, MD, PhD; Camilla Matheisen; Francois Iglesias; Radoiane Helbaj; Oliver Krieter; Michael Hettich; | Completed Clinical Trials | Bispecifics; Clinical study; Clinical trial; Solid tumors; T cell; Tumor microenvironment; Tumor stroma |
| 287 | Poster Presentation | Safety and antitumor activity of indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor KHK2455 in combination with anti-CCR4 monoclonal antibody mogamulizumab in patients with advanced solid tumors | Solmaz Sahebjam, MD; Jameel Muzaffar, MD; Timothy A. Yap, MD, PhD; David S. Hong, MD; Olivier Rixe, MD, PhD; Ursa Brown-Glaberman, MD; Andreea Varga, MD; Christophe Massard, MD; Capucine Baldini, MD; Sergey Efuni, MD, PhD; Barbara Kapelan, BS; Yi Liu, PhD; Eniola Ogunmefun, MD; Tomonori Tayama, MS; Henry Zhao, PhD; Denis J. Healy, MBA; Robert Latek, PhD; Daisuke Nakashima, MS; Emrullah Yilmaz, MD, PhD | Completed Clinical Trials | Antibody; Biomarkers; Clinical study; Clinical trial; Regulatory T cell (Treg cell); Solid tumors |
| 288 | Poster Presentation | A Phase 1 Study of IMC-001, a PD-L1 Blocker, in Patients with Metastatic or Locally Advanced Solid Tumors | Bhumsuk Keam, MD, PhD; Tae Min Kim, MD, PhD; Do-Youn Oh, MD, PhD; Chan-Young Ock, MD, PhD; Won Ki Kang, MD, PhD; Yeon Hee Park, MD, PhD; Jeeyun Lee, MD, PhD; Ji Hye Lee, MD; Yun Jeong Song, MD; Young Suk Park, MD, PhD; | Completed Clinical Trials | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; T cell |
| 289 | Poster Presentation | PGV-001: A Phase 1 Trial of a Personalized Neoantigen Peptide Vaccine for the Treatment of Malignancies in the Adjuvant Setting. | Thomas U. Marron, MD, PhD; Julia Kodysh, PhD; Alex Rubinsteyn, PhD; John Finnigan, MD PhD; Ana Blazquez, PhD; Mansi Saxena, PhD; Marcia Meseck; Timothy O’Donnell; Daniela Delbeau, RN; Matthew Galsky, MD; Deborah , Doroshow, MD PhD; Brett Miles, MD; Krysztof Misiukiewicz, MD; Hanna Irie, MD PhD; Amy Tiersten, MD; Samir Parekh, MD; Marshall Posner, MD; Andrea Wolf, MD MPH; John Mandeli, PhD; Jeffrey Hammerbacher, PhD; Michael Donovan, MD PhD; Rachel Brody, MD PhD; Sacha Gnjatic, PhD; Eric Schadt, PhD; Philip Friedlander, MD PhD; Nina Bhardwaj, MD PhD; | Completed Clinical Trials | Clinical trial; Immune monitoring; Neoantigens; Solid tumors; Vaccine |
| 290 | Poster Presentation | Cytokine and immune subset signatures in patients with various solid and hematological malignancies treated with oncolytic vaccinia virus delivered by autologous stromal vascular fraction cells | Dobrin Draganov, PhD; Antonio F. Santidrian; Ivelina Minev, MSc; Duong H. Nguyen, PhD; Dmitriy Zamarin, MD, PhD; Francesco M. Marincola, MD; Boris Minev, MD; | Completed Clinical Trials | Adoptive immunotherapy; Antigen presenting cells; Clinical study; Immune monitoring; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors; Stem cell/cancer-initiating cell; T cell; T cell lineages |
| 291 | Poster Presentation | Phase Ib Study of Selicrelumab (CD40 agonist) in Combination with Atezolizumab (anti-PD-L1) in Patients with Advanced Solid Tumors | Fabrice Barlesi, Prof, MD, PhD; Martijn Lolkema, MD, PhD; Kristoffer Staal Rohrberg, MD, PhD; Cinta Hierro, MD; Aurelien Marabelle, MD, PhD; Albiruni Abdul Razak, MD; Luis Teixeira, MD, PhD; Valentina Boni, MD, PhD; Wilson H. Miller, Jr, MD, PhD; Charu Aggarwal, MD, MPH; Martin Stern, MD; Olivera Cirovic, MD, PhD; Olivera Cirovic, MD, PhD; Barbara Romagnoli, PhD; Randolph Christen, MD; Raksha Dodia, PhD; Kevin Smart, PhD; Bernhard Reis, PhD; Nicolas Staedler, PhD; Carl Watson; Neeltje Steeghs, MD, PhD; | Completed Clinical Trials | Antigen presenting cells; Checkpoint blockade; Clinical study; Solid tumors |
| 292 | Poster Presentation | Immune checkpoint inhibitor induced overlapping cardiac and neuromuscular toxicities: Highlight of early diagnosis, early initiation of immunosuppressive therapy and multidisciplinary management | HoWai D. Siu, MBBS, MMed; Robert S. O'Neill, MedSci MBBS; Matthew H. Tong, MD; JunHee Hong, Bmed, MD; Carole A. Harris, MBBS (Hons) MMed BPharm FRACP; Morteza Aghmesheh, MD, GradDipSC, PhD, FRACP; Hussein S. Hussein, Dr; | Completed Clinical Trials | Checkpoint blockade; Immune suppression; Immune toxicity; Inflammation |
| 293 | Poster Presentation | Results of the first-in-human clinical trial with personalized multi-target adoptive cell therapy (ACTolog IMA101) | Apostolia M. Tsimberidou, MD, PhD; Apostolia M. Tsimberidou, MD, PhD; Apostolia M. Tsimberidou, MD, PhD; Kerstin Guenther; Amir Alpert; Borje Andersson, MD, PhD; Zoe Coughlin; Jens Fritsche, PhD; Norbert Hilf; Patrick M. Hwu, MD; Mamta Kalra, PhD; Sabrina Kuttruff-Coqui, PhD; Dominik Maurer, PhD; Regina Mendrzyk; Ali Mohamed; Becky Norris; Anna Nowak; Rita Ort; Carsten Reinhardt, MD, PhD; Fabian Richter; Arun Satelli; Oliver Schoor, PhD; Kerry A. Sieger; Harpreet Singh, PhD; David Vining, MD; Claudia Wagner; Toni Weinschenk, PhD; Cassian Yee, MD; Steffen Walter, PhD; | Completed Clinical Trials | Adoptive immunotherapy; Biomarkers; Checkpoint blockade; Clinical trial; Immune monitoring; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| 294 | Oral Presentation | CD8 PET imaging of tumor infiltrating T cells in advanced solid tumors: a phase I first-in-human study of 89Zr-IAB22M2C, a radiolabeled anti-CD8 minibody | Michael D. Farwell, MD; Raymond F. Gamache, PhD; Neeta Pandit-Taskar, MD; Mike Postow, MD; Michael S. Gordon; Ian A. Wilson, PhD; Alessandro Mascioni, PhD; Anna M. Wu, PhD; William Le; Avital Weiss; Ronald Korn, MD PhD; | Completed Clinical Trials | Biomarkers; Clinical study; Clinical trial; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 295 | Poster Presentation | First-in-human Phase I trial of IBI188, an anti-CD47 targeting monoclonal antibody, in patients with advanced solid tumors and lymphomas | Nehal Lakhani, MD, PhD; Marlana Orloff, MD; Siqing Fu, MD, PhD; Ying Liu; Yan Wang; Hui Zhou; Kedan Lin, PhD; Fang Liu; Shuling Yan; Amita Patnaik, MD FRCP(C) | Completed Clinical Trials | Autoimmunity; Clinical trial; Immune toxicity |
| 296 | Poster Presentation | Immune correlates of clinical response to Avelumab in patients with advanced thymic epithelial tumors | Yo-Ting Tsai, PhD; Arun Rajan, MD; James L. Gulley, MD, PhD; Jeffrey Schlom, PhD; Renee N. Donahue, PhD; | Completed Clinical Trials | Autoimmunity; B cell; Biomarkers; Checkpoint blockade; Immune monitoring; Solid tumors |
| 297 | Poster Presentation | Modeling the efficacy of NY-ESO-1 TCR T cells (letetresgene autoleucel; GSK3377794) in patients with synovial sarcoma: correlations of response with transduced cell kinetics and biomarkers | Alexandra Gyurdieva; Stefan Zajic; Ya-Fang Chang; E. Andres Houseman; Shan Zhong; Jaegil Kim; David C. Turner; Laura A. Johnson; Ioanna S. Eleftheriadou; Jenna Tress; Aisha N. Hasan, MBBS MD; Victoria L. Chiou; Naimish Pandya; John Glod, MD; Dejka Araujo, MD; Warren Chow; Mihaela Druta; George D. Demetri; Brian A. Van Tine, MD, PhD; Sandra P. D’Angelo; | Completed Clinical Trials | Adoptive immunotherapy; Biomarkers; Chemokine; Cytokine; Gene expression; Immune monitoring; Pediatric tumors; Solid tumors; T cell; Targeted therapy |
| 298 | Poster Presentation | Final analysis of the Phase 1 trial of NY-ESO-1–specific T-cell receptor (TCR) T-cell therapy (letetresgene autoleucel; GSK3377794) in patients with advanced synovial sarcoma (SS) | Sandra P. D'Angelo, MD; George D. Demetri; Brian A. Van Tine, MD, PhD; Mihaela Druta; John Glod, MD; Warren Chow; Naimish Pandya; Aisha N. Hasan, MBBS MD; Victoria L. Chiou; Jenna Tress; Julie Edwards; Tim Young; Mary Woessner; Alexandra Gyuerdieva; Stefan Zajic; Sophia Goodison; Dejka Araujo, MD; | Completed Clinical Trials | Adoptive immunotherapy; Clinical trial; Solid tumors; T cell; Tumor antigens |
| 299 | Poster Presentation | Immuno-Metabolic Signatures of Dendritic Cells Associate With T-cell Responses in Melanoma Patients | Juraj Adamik, PhD; Deena M. Maurer, MS; Paul Munson, PhD; Alexis J. Combes, PhD; Philippe Pierre, PhD; Matthew F. Krummel, PhD; Rafael J. Argüello, PhD; Lisa H. Butterfield, PhD; | Completed Clinical Trials | Antigen presenting cells; Dendritic cell; Gene expression; Metabolism; Vaccine |
| 300 | Poster Presentation | Final analysis of a prospective, randomized, double-blind, placebo-controlled phase IIb trial of tumor lysate, particle-loaded, dendritic cell vaccine in stage III/IV melanoma: 36-month analysis | Lexy M. Adams, MD, MPH; Robert C. Chick, M.D.; Guy T. Clifton, MD; Timothy J. Vreeland, BS MD; Patrick M. McCarthy, MD; Anne E. O'Shea, MD; Phil M. Kemp Bohan, MD; Annelies T. Hickeron, MD; John W. Myers, MD; Jessica L. Cindass, MD; Diane F. Hale, MD; Mark B. Faries, MD; John Hyngstrom, MD; Adam C. Berger, FACS, MD; James W. Jakub, MD; Jeffrey J. Sussman, MD; Montaser F. Shaheen, MD; Thomas E. Wagner, BS, MD; George E. Peoples, MD, FACS; | Completed Clinical Trials | Clinical trial; Dendritic cell; Solid tumors; Tumor antigens; Vaccine |
| 301 | Poster Presentation | Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study | Paolo A. Ascierto, MD; Karl D. Lewis, MD; Caroline Robert, MD, PhD; Daniil Stroyakovskiy, MD, PhD; Helen Gogas, MD, PhD; Svetlana Protsenko, MD, DSc; Rodrigo P. Pereira, MD; Thomas Eigentler, MD; Piotr Rutkowski, MD; Lev Demidov, MD, DSc; Georgy Moiseevich Manikhas, MD, PhD; Haocheng Li, PhD; Qian Zhu, PhD; Edward McKenna, PharmD, BCOP; Virginia McNally, PhD; Ralf Gutzmer, MD; Grant A. McArthur, MBBS (Hons), PhD, FRACP, FAHMS; | Completed Clinical Trials | Checkpoint blockade; Clinical study; Solid tumors; Targeted therapy |
| 302 | Poster Presentation | A phase I trial of intratumoral PVSRIPO in patients with unresectable treatment refractory melanoma | Georgia M. Beasley, MD, MHs; Nellie E. Farrow, MD; Karenia Landa, MD; Maria Angelica Selim, MD; Sin-Ho Jung, PhD; Darell D. Bigner, MD, PhD; Andrea True Kelly, PhD; Smita Nair, PhD; Matthias Gromeier, MD; April Salama, MD; | Completed Clinical Trials | Clinical trial; Solid tumors; Vaccine |
| 303 | Oral Presentation | Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (IT) CMP-001 in High-Risk Resectable Melanoma (Neo-C-Nivo): Final Results. | Diwakar Davar, MD; Arivarasan Karunamurthy; Douglas Hartman; Richelle DeBlasio, B.Sc.; Joe-Marc JM. Chauvin, PhD; Quanquan Ding; Ornella Pagliano; Amy Rose, RN; John M. Kirkwood, MD; Hassane M. Zarour, MD; | Completed Clinical Trials | Checkpoint blockade; Clinical trial; Immune contexture; TLR |
| 304 | Poster Presentation | Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma | Mohammed M. Milhem, MBBS; Yousef Zakharia, MD; Diwakar Davar, MD; Elizabeth I. Buchbinder, MD; Theresa Medina, MD; Adil Daud, MD; Antoni Ribas, MD, PhD; Jiaxin Niu, MD, PhD; Geoffrey T. Gibney, MD; Kim A. Margolin, MD; Anthony J. Olszanski, MD, RPh; Inderjit Mehmi, MD; Takami Sato, MD; Montaser Shaheen, MD; Aaron J. Morris, PhD; David Mauro, MD, PhD; Katie Campbell, PhD; Heather Kelley, MA; Riyue Bao, PhD; George J. Weiner, MD; Jason J. Luke, MD; Arthur M. Krieg, MD; James E. Wooldridge, MD; John M. Kirkwood, MD; | Completed Clinical Trials | Checkpoint blockade; Clinical study; Dendritic cell; T cell; TLR; Tumor microenvironment |
| 305 | Poster Presentation | Technical considerations for normalizing digital spatial profiling data with multiple within-patient samples | Tyler D. Hether; Tim Howes, PhD; Christine N. Spencer, PhD; Travis Hollman, PhD, MD; Jason W. Reeves; Danny Wells, BA, PhD; Claire F. Friedman, MD; Theresa LaVallee; Jedd D. Wolchok, MD, PhD; Sarah E. Warren, PhD; | Completed Clinical Trials | Antibody; Bioinformatics; Biomarkers; Clinical trial; Gene expression; RNA; Solid tumors; Tumor microenvironment; Tumor stroma |
| 306 | Poster Presentation | Predictors of immunotherapy benefit in Merkel cell carcinoma | Alec J. Kacew, BA; Harita Dharaneeswaran; Gabriel J. Starrett; Manisha Thakuria; Nicole R. LeBoeuf, MD, MPH; Ann W. Silk, MD, MS; James A. DeCaprio; Glenn J. Hanna, MD; | Completed Clinical Trials | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors |
| 307 | Poster Presentation | Atezolizumab plus vemurafenib and cobimetinib provides favorable survival outcomes in patients with high tumor mutation burden and proinflammatory gene signature in the phase 3 IMspire150 study | Karl D. Lewis, MD; Paolo A. Ascierto, MD; Caroline Robert, MD, PhD; Rodrigo Munhoz, MD; Gabriella Liszkay, MD; Luis De La Cruz Marino, MD; Judit Olah, MD; Paola Queirolo, MD; Jacek Mackiewicz, MD, PhD; Kalpit Shah, PhD; Harper Forbes, MSc; Christian Hertig, PhD; Yibing Yan, PhD; Ralf Gutzmer, MD; Grant A. McArthur, MBBS (Hons), PhD, FRACP, FAHMS; | Completed Clinical Trials | Checkpoint blockade; Clinical study |
| 308 | Poster Presentation | Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for melanoma | Jeffrey S. Weber, MD, PhD; Paolo A. Ascierto, MD; Mark R. Middleton, MD, PhD; Delphine Hennicken; Roberto Zoffoli; Anne Pieters; Adenike Amadi; Katrin Kupas; Srividya Kotapati; Andriy Moshyk, MSc, MD; Dirk Schadendorf, MD; | Completed Clinical Trials | Checkpoint blockade; Immune adjuvant; Solid tumors |
| 309 | Poster Presentation | The role of tumor-draining lymph nodes in the tuning of systemic T cell immunity by CTLA-4 blockade is revealed by local delivery of tremelimumab in early-stage melanoma: data from a Phase-I trial | Jessica C. Notohardjo, MD; Kim M. van Pul, MD; Anita G. Stam; Dafni Chondronasiou; Sinead Lougheed; Petrousjka M. van den Tol; Karin Jooss, PhD; Ronald J. Vuylsteke, MD, PhD; Alfons J. van den Eertwegh; Tanja D. de Gruijl, PhD; | Completed Clinical Trials | Checkpoint blockade; Clinical study; Dendritic cell; Immune adjuvant; Immune monitoring; MDSC; T cell; TLR; Tumor microenvironment |
| 310 | Poster Presentation | The effect of pretreatment with G-CSF prior to dendritic cell collection during the phase IIb trial of an autologous DC-based vaccine for advanced, resectable melanoma | Anne E. O'Shea, MD; Robert C. Chick, M.D.; Guy T. Clifton, MD; Timothy J. Vreeland, BS MD; Lexy M. Adams, MD, MPH; Patrick M. McCarthy, MD; Phillip M. Kemp Bohan, MD; Annelies T. Hickeron, MD; John W. Myers, MD; Jessica L. Cindass, MD; Tommy A. Brown, MD; Diane F. Hale, MD; Mark B. Faries, MD; John Hyngstrom, MD; Adam C. Berger, FACS, MD; James W. Jakub, MD; Jeffrey J. Sussman, MD; Montaser F. Shaheen, MD; Thomas E. Wagner, BS, MD; George E. Peoples, MD, FACS; | Completed Clinical Trials | Antigen presenting cells; Clinical trial; Dendritic cell; Solid tumors; Tumor antigens; Vaccine |
| 311 | Poster Presentation | Phase II Trial of Lymphodepletion Plus Adoptive Cell Transfer with or Without Dendritic Cell Vaccination in Patients with Metastatic Melanoma | Chantal Saberian, MD; Rodabe N. Amaria, MD; Cara Haymaker, PhD; Marie Andree Forget, PhD; Roland L. Bassett, BS; Isabella C. Glitza, MD, PhD; Gregory A. Lizee, PhD; Cassian Yee, MD; Jeniffer L. McQuade, MD; Michael K. Wong, MD PhD FRCPC; Hussein A. Tawbi, MD, PhD; Sapna Patel, MD; Adi Diab, MD; Michael A. Davies, MD, PhD; Patrick M. Hwu, MD; Chantale Bernatchez, PhD; | Completed Clinical Trials | Antigen presenting cells; Clinical study; Clinical trial; Dendritic cell; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
| 312 | Poster Presentation | Female sex independently predicts adjuvant immunotherapeutic benefit from CTLA4 immune checkpoint inhibition | Ahmad A. Tarhini, MD, PhD, MS; Ni Kang; Sandra Lee; F. Stephen Hodi, Jr., MD; Gary I. Cohen; Omid Hamid, MD; Laura F. Hutchins; Jeffrey A. Sosman, MD; Harriett M. Kluger; Zeynep Eroglu, MD; Henry Koon, MD; Donald P. Lawrence, MD; Kari L. Kendra; David R. Minor, MD; Carrie Lee, RN, MSN, OCN; Mark R. Albertini, MD; Lawrence E. Flaherty, MD; Teresa Petrella; Howard Striecher; Vernon K. Sondak, MD; John M. Kirkwood, MD; | Completed Clinical Trials | Biomarkers; Checkpoint blockade; Clinical trial; Immune tolerance; Solid tumors |
| 788 | Oral Presentation | Pembrolizumab for Patients with Leptomeningeal Metastasis from Solid Tumors: Efficacy, Safety and Cerebrospinal Fluid Biomarkers | Jarushka Naidoo, MB BCH MHS; Karisa C. Schreck; Wei Fu; Chen Hu; Roisin M. Connolly, MD; Cesar A. Santa-Maria, MD, MSCI; Evan J. Lipson, MD; Matthias Holdhoff; Patrick Forde, MD; Joanne Riemer, RN BSN; Amanda Barnes; Nafi Aygun; Lawrence Kleinberg; Kristin Redmond; Christopher Douville; Chetan Bettegowda; Arun Venkatesan; Stuart Grossman; Julie R. Brahmer, MD, MS; | Completed Clinical Trials | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Cytokine |
| 789 | Poster Presentation | Intratumoral plasmid IL-12 expands CD8+ T cells and induces a clinically validated CXCR3 signature in triple-negative breast cancer | Erika J. Crosby, Ph.D.; Hiroshi Nagata; Melinda Telli; Chaitanya R. Acharya; Irene Wapnir; Kaitlin Zablotsky; Erica Browning, BS; Reneta Hermiz; Lauren Svenson; Donna Bannavong; Kellie Malloy; David A. Canton, PhD; Christopher G. Twitty, PhD; Takuya Osada; Herbert K. Lyerly, MD; | Completed Clinical Trials | Biomarkers; Checkpoint blockade; Chemokine; Clinical study; Immune tolerance; MDSC; T cell; Tumor microenvironment |
| 790 | Poster Presentation | A Phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC) | Matthew G. Krebs, MD, PhD; Margarita Majem; Enriqueta Felip, MD PhD; Martin Forster; Bernard Doger; Tim Clay; Enric Carcereny, MD; Julio A. Peguero, MD; Leora Horn; Pawan Bajaj; Patricia Roxburgh; Chrystelle Brignone; Christian Mueller, MSc; Frederic Triebel; | Completed Clinical Trials | Antigen presenting cells; Checkpoint blockade; Clinical study; Clinical trial; Dendritic cell |
| 791 | Poster Presentation | A Phase II Study of the Anti-Programmed Cell Death-1 (PD-1) Antibody Penpulimab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) | Yuqin Song, MD; Keshu Zhou, MD; Chuan Jin, MD; Zhengzi Qian, MD; Ming Hou, MD; Lei Fan, MD; Fei Li, MD; Kaiyang Ding, MD; Hui Zhou, MD; Xiaoling Li, MD; Bing Chen, MD; Xiuhua Sun, MD; Xianmin Song, MD; Ming Jiang, MD; Qingyuan Zhang, MD; Lihong Liu, MD; Guohua Yu, MD; Yu Hu, MD; Zheng Zhao, MD; Ligen Liu, MD; Hongwei Xue, MD; Jun Luo, MD; Bai He, MD; Xiaoping Jin, PhD; Maxwell Wang, PhD; Baiyong Li, PhD; Yu Xia, PhD; Jun Zhu, MD; | Completed Clinical Trials | Checkpoint blockade; Clinical study; Clinical trial |
| 793 | Poster Presentation | TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) Human Papilloma Virus (HPV)-16+ cancers: clinical efficacy and immunogenicity | Christophe Le Tourneau, MD, PhD; Philippe Cassier, MD; Frederic Rolland; Sébastien Salas; Jean Marc Limacher, MD, MSc; Olivier Capitain; Olivier Lantz; Ana Lalanne; Christina Ekwegbara; Annette Tavernaro; Hakim Makhloufi; Kaidre Bendjama; Jean-Pierre Delord, MD; | Completed Clinical Trials | Antibody; Checkpoint blockade; Clinical trial; Immune contexture; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment; Vaccine |
| 794 | Poster Presentation | Safety and efficacy results from a phase 1/1b study of intratumoral MK-4621, a retinoic acid-inducible gene I (RIG-I) agonist, plus intravenous pembrolizumab in patients with advanced solid tumors | Victor Moreno, PhD, MD; Caroline Gaudy-Marqueste; Martin Wermke, MD; Antoine Italiano, MD; Emanuela Romano, MD, PhD; Aurelien Marabelle, MD, PhD; Emilee Connors, PhD; Heng Zhou; Konstantin Dobrenkov, MD; Elliot Chartash, MD; Emiliano Calvo, MD PhD; | Completed Clinical Trials | Checkpoint blockade; Clinical trial; Solid tumors |
| 795 | Oral Presentation | A multicenter phase II trial (SWOG S1609, Cohort 51) of Ipilimumab and Nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) | Michael J. Wagner, M.D.; Megan Othus; Sandip P. Patel, M.D.; Christopher W. Ryan; Ashish Sangal; Benjamin Powers; George T. Budd; Adrienne I. Victor; Chung-Tsen Hsueh; Rashmi Chugh; Suresh Nair; Kirsten M. Leu; Mark Agulnik, MD; Elad Sharon, MD, MPH; Edward Mayerson; Melissa Plets, M.S.; Charles D. Blanke; Howard Streicher, MD; Young Kwang Chae, MD, MPH, MBA; Razelle Kurzrock; | Completed Clinical Trials | Checkpoint blockade; Clinical study; Clinical trial; Coinhibition; Solid tumors |
| 796 | Poster Presentation | A phase I/II trial combining Avelumab and Trabectedin for advanced liposarcoma and leiomyosarcoma | Michael J. Wagner, M.D.; Qianchuan He; Yuzheng Zhang; Lee Cranmer; Elizabeth T. Loggers; Sabrina McDonnell; Shannon Maxwell; Seth M. Pollack, MD; | Completed Clinical Trials | Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; Monocyte/Macrophage; T cell |
| 797 | Poster Presentation | Significant anti-tumor activity of HBI-8000, a class I histone deacetylase inhibitor (HDACi) in combination with nivolumab (NIVO) in anti-PD1 therapy-naïve advanced melanoma (TN-Mel) | Nikhil I. Khushalani, MD; Andrew S. Brohl, MD; Joseph Markowitz, MD, PhD; Lyudmila Bazhenova, MD; Gregory A. Daniels, MD, PhD; Heather Yeckes-Rodin, MD; Siqing Fu, MD, PhD; Lori M. McCormick, RN; Michael Kurman, MD; Mireille Gillings, PhD, Hon DSc; Gloria Lee, MD, PhD; Zeynep Eroglu, MD; | Completed Clinical Trials | Epigenetics; Checkpoint blockade; Clinical study; Clinical trial |
